Acitretin

Active ingredient description

Acitretin, a synthetic aromatic derivative of retinoic acid, has a favourable therapeutic ratio, with a greater and more specific inhibitory effect on psoriasis and disorders of epithelial keratinisation. The usual therapeutic response to acitretin consists of desquamation (with or without erythema) followed by more normal re-epithelialisation. Acitretin is the main active metabolite of etretinate.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
Acitretin
D Dermatologicals → D05 Antipsoriatics → D05B Antipsoriatics for systemic use → D05BB Retinoids for treatment of psoriasis
Discover more medicines within D05BB02

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
Summary of Product Characteristics (SPC)
UK
Structured Product Labeling (SPL)
US

Medicines

Acitretin is the active ingredient of these drugs:

Drug
Countries

Poland

Austria

Australia Brazil Estonia Finland Hong Kong

Australia

New Zealand Singapore

Turkey

Canada France United States

Hong Kong

Australia

Italy

Structural formula

Graphic representation of the active ingredient's molecular structure

Chemical formula: C₂₁H₂₆O₃
Molecular mass: 326.429 g/mol

External identifiers

CAS Substance: 55079-83-9
DrugBank Drug: DB00459
KEGG Drug: D02754
PubChem Compound: 5284513
RxNorm Ingredient: 16818
SNOMED-CT Concept: 386938006
Acitretin (substance)
UNII Identifier: LCH760E9T7
ACITRETIN